Cosmo Godino

Cosmo Godino

Auto-generated profile, based on publicly available information

Cosmo Godino

Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2007 in Circulation
Verified
Journal Article
Closed access
PDF file
FAFlavio Airoldi
Flavio Airoldi
ACAntonio Colombo
Antonio Colombo
NMNuccia Morici
Nuccia Morici
Azeem LatibAzeem Latib
Azeem Latib
JCJohn Cosgrave
John Cosgrave
EGEberhard Grube
Eberhard Grube
Background— The need for prolonged aspirin and thienopyridine therapy and the risk of stent thrombosis (ST) remain as drawbacks associated with drug-eluting stents. Methods and Results— A prospective observational cohort study was conducted between June 2002 and January 2004 on 3021 patients consecutively and successfully treated in 5389 lesions with drug-eluting stents. Detailed patient information was collected on antiplatelet therapy. We analyzed the incidence of ST throughout the 18-month follow-up period and its relationship with thienopyridine therapy. ST occurred in 58 patients (1.9%) at 18 months. Forty-two patients (1.4%) experienced the event within 6 months of stent implantation. Acute myocardial infarction (fatal or nonfatal) occurred in 46 patients (79%) and death in 23 patients (39%) with ST. The median interval from discontinuation of thienopyridine therapy to ST was 13.5 days (interquartile range 5.2 to 25.7 days) for the first 6 months and 90 days (interquartile range 30 to 365 days) between 6 and 18 months. On multivariable analysis, the strongest predictor for ST within 6 months of stenting was discontinuation of thienopyridine therapy (hazard ratio, 13.74; 95% CI, 4.04 to 46.68; P <0.001). Thienopyridine discontinuation after 6 months did not predict the occurrence of ST (hazard ratio, 0.94; 95% CI, 0.30 to 2.98; P =0.92). Conclusions— Discontinuation of thienopyridine therapy was the major determinant of ST within the first 6 months, but insufficient information is available to determine whether there is benefit in continuing a thienopyridine beyond 6 months.

1 September 2011 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
RMRoxana Mehran
Roxana Mehran
BCBimmer Claessen
Bimmer Claessen
CGCosmo Godino
Cosmo Godino
GDGeorge D. Dangas
George D. Dangas
KOKotaro Obunai
Kotaro Obunai
ACAntonio Colombo
Antonio Colombo

1 January 2011 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
RARasha Al-Lamee
Rasha Al-Lamee
AIAlfonso Ielasi
Alfonso Ielasi
Azeem LatibAzeem Latib
Azeem Latib
CGCosmo Godino
Cosmo Godino
MFMassimo Ferraro
Massimo Ferraro
ACAntonio Colombo
Antonio Colombo

1 June 2010 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
ACAlaide Chieffo
Alaide Chieffo
VMValeria Magni
Valeria Magni
Azeem LatibAzeem Latib
Azeem Latib
FMFrancesco Maisano
Francesco Maisano
AIAlfonso Ielasi
Alfonso Ielasi
ACAntonio Colombo
Antonio Colombo

1 December 2020 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
CGCosmo Godino
Cosmo Godino
AMAndrea Munafò
Andrea Munafò
ASAndrea Scotti
Andrea Scotti
RERodrigo Estévez-Loureiro
Rodrigo Estévez-Loureiro
AHAntonio Portolés Hernández
Antonio Portolés Hernández
FSFrancesco Saia
Francesco Saia

1 November 2010 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
CGCosmo Godino
Cosmo Godino
FMFrancesco Maisano
Francesco Maisano
MMMatteo Montorfano
Matteo Montorfano
Azeem LatibAzeem Latib
Azeem Latib
ACAlaide Chieffo
Alaide Chieffo
ACAntonio Colombo
Antonio Colombo